NY-IFF
30.11.2022 22:21:40 CET | Business Wire | Press release
IFF (NYSE: IFF) has named Dennis Maroney Master Perfumer, an honor recognizing his career achievements, entrepreneurial contributions and record of commercial excellence in the global perfumery industry. Maroney is a 32-year industry veteran and IFF’s ninth Master Perfumer, a distinction reserved for those who have demonstrated exceptional leadership and measurable impact in perfumery.
“Dennis has demonstrated a unique ability to bring together science and creativity, with a strong, undefeatable sense of purpose,” said Frank Clyburn, CEO, IFF. “He is a humble leader and an inspiring mentor who has created milestone scent signatures in the beauty and home care world. His unique contributions to the products we use every day in our beauty and home care routines are truly inspiring, and this Master Perfumer recognition is more than deserved.”
Commenting on his Master Perfumer appointment, Maroney said: “Perfumery is about transporting the consumer to a time and place where they are happy. It is about bringing a positive impact to someone’s day with something I have created. It is about making them smile, making their life smell better, and making that experience last long enough that when they come back to real life, the sunshine is still there in the air, vibrant with peace and courage.”
Maroney was born in Elmsford, NY, and as a child, was driven by a desire to solve problems. After earning a bachelor’s of science in Psychology from the University of Connecticut, he joined Kato, a fragrance house, as laboratory assistant, where he was trained in the art of perfumery by senior perfumers. After holding perfumer positions of increasing responsibility, Maroney joined IFF predecessor Bush Boake Allen in 1998. Since then, he has created globally recognized signatures in hair and beauty products, and across home consumer products. Additionally, Maroney is a five-time winner of the American Society of Perfumers “Perfumer Choice Awards,” and served as the organization’s president and chairman of the board between 2010 and 2014.
“Dennis’ innovation-driven mindset, leadership and creativity have helped develop groundbreaking scent solutions with breakthrough technologies, bridging A.I. and scientifically driven wellness research,” said Christophe de Villeplée, president, Scent, IFF. “Over the years, Dennis has created some of the most iconic fragrances and signatures across multiple categories. He has played an instrumental role in mentoring IFF junior perfumers and perfumery students, ensuring the next generation of perfumers have the creative, technical and innovation skills to create novel, memorable fragrances consumers desire.”
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
© 2022 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130006055/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release
Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release
Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press release
Southern California-Based Company has developed a disruptive biosensor for integration into next-generation screening and diagnostic devices Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom